Die Hoffotografen GmbHSolid tumours pose major obstacles for cell therapies, but German-American biotech T-knife is tackling them head-on. CEO Tom Soloway and CTO Elisa Kieback share how their “supercharged” TCR-Ts are engineered to overcome these challenges.
Boehmert & BoehmertNew developments under the current U.S. administration may be a challenge for the pharma/biotech industry: the Inflation Reduction Act, Orange Book Challenges, Most Favored Nation Policy, and the new Trump-Lutnick Patent Tax. And it will likely affect European pharma and biotech.
AseBio Out of 43 pitches, the founders of Spanish Opportunity Health S.L. delivered the best presentation for a new life sciences product: a choking device that can potentially be used by anyone in emergency situations without the need for external assistance.
AseBioAlongside a start-up pitch featuring 45 international participants, the second day of BioSpain 2025 (7–9 October 2025, Barcelona) offered biotech start-ups a panel discussion with prominent US investors, who shared their selection criteria and outlined the impact of the current geopolitical situation on investment decisions.
https://www.chimia.ch/chimia/article/view/2025_292Switzerland is a key hub for biomanufacturing, with immunological products like antibodies
and vaccines making up 18.5% of 2024 exports. Swiss companies drive biotech innovation and biocatalysis
across sectors globally, extending the traditional focus on pharmaceuticals to fine chemicals, fragrances
and food tech. The development is supported by national collaborations and international coalitions.
AseBioSpain has once again secured the top position in Europe for clinical trials. According to various Clinical Research Organisations at BioSpain 2025 (7–9 October, Barcelona), this is largely due to the speed with which the Spanish Medicines Agency (AEMPS) approves clinical studies.
Kinga Lubowiecka/ EMBLThe EMBL Imaging Centre has received €7 million in support from Boehringer Ingelheim Stiftung to further advance its cutting-edge imaging technologies.
SPRINDBiomanufacturing promises domestic, sustainable, sovereign and resilient production. Capacities are trapped in outdated scale-up processes. SPRIND urges investment and disruptive innovation to propel biomanufacturing. Demands are decentralised, non-sterile & continuous biomanufacturing capabilities.
Resilience and quality connections define Chemspec Europe 2025.
MedicalWorks from Adobe StockA landmark study in the UK shows that mitochondrial replacement therapy can prevent babies from inheriting diseases caused by mutant mitochondria.